论文部分内容阅读
文章综述第48届美国临床肿瘤学会年会中关于小细胞肺癌(SCLC)的研究进展。同步放化疗是局限期SCLC患者的标准治疗,化疗方案推荐EP方案,从第3周期化疗开始放疗也可以作为其选择;在广泛期SCLC的化疗中氨柔比星联合顺铂(AP)方案劣于伊立替康联合顺铂(IP)方案,在足叶乙甙联合卡铂(EC)方案基础上加恩度未能提高生存期;拓扑替康联合阿柏西普在铂类经治的患者中值得进一步研究;循环肿瘤细胞数量下降与SCLC治疗有效相关,c-Met可作为SCLC的独立预后因子,女性是较好生存期的阳性预后因子;SCLC患者中存在较低的EGFR突变。
This review summarizes the progress of small cell lung cancer (SCLC) in the 48th annual meeting of the American Society of Clinical Oncology. Concurrent chemoradiation is the standard treatment for patients with localized SCLC. The EP regimen is recommended for the chemotherapy regimen, and radiotherapy is also available from the start of cycle 3 chemotherapy. In extensive SCLC chemotherapy, the combination of amrubicin and cisplatin (AP) In irinotecan combined with cisplatin (IP) program, etoposide combined with carboplatin (EC) regimen failed to improve survival; Topotecan combined with aflibercept in platinum treated patients The median deserves further study; decreased number of circulating tumor cells is associated with the effective treatment of SCLC, c-Met can be used as an independent prognostic factor for SCLC, women are positive prognostic factors for better survival; SCLC patients with lower EGFR mutations.